As 2020 draws to a close, Dr Bruce Henderson (CEO) reviews the major advances and developments at Altair Medical during the year.
As Covid 19 has accelerated the adoption of Digital Health technology, Altair’s AI driven remote respiratory monitoring platform has proven to be of enormous interest to a large number of healthcare providers and commercial partners as we all seek to address the needs of respiratory patients currently unmet by existing technology.
Even before the pandemic, market pull had broadened our product focus to embrace all respiratory illness, rather than the previous focus on opioid related monitoring, and this has opened up a range of opportunities.
Our key successes in 2020 include:
In addition, we have:
All of this brings us closer to regulatory approval via the Breakthrough Device Program awarded to Altair by the US FDA – a program for innovative, life-saving medical technology that offers substantial advantages over existing approved or cleared devices. As well as priority review for regulatory clearance, the program offers rapid US insurer approval and access to our primary market in advance of global expansion.
The range and diversity of unmet needs that our technology has the potential to address is generating a momentum to the business that is exciting to be a part of. I hope you agree that 2020 has been a great year for us, but there is plenty to work on in 2021.
If you would like to hear more on any of these points, please do not hesitate to get in touch.
Enjoy the holiday season and I hope to speak to you in the New Year.
Dr Bruce Henderson
CEO
Altair Medical Limited